[Randomised phase II study evaluating oral combination chemotherapy (CCNU, cyclophosphamide, etoposide) and intravenous chemotherapy as second-line treatment for relapsed small cell bronchial carcinoma (Trial GFPC0501)]

Autor: Gervais, R., Le Guen, Y., Le Caer, H., Paillotin, D., Chouaid, C., Renseigné, Non
Přispěvatelé: Annesi-Maesano, Isabella, IFP Energies nouvelles (IFPEN), Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), R Gervais, Le Guen Y, H Caer Le, Paillotin D, Chouaid C, GFPC
Jazyk: francouzština
Rok vydání: 2007
Předmět:
MESH: Remission Induction
MESH: Survival Rate
MESH: Antineoplastic Agents
Phytogenic
Administration
Oral
MESH: Vincristine
MESH: Lomustine
MESH: Antineoplastic Agents
Alkylating
MESH: Health Resources
MESH: Doxorubicin
Lomustine
Antineoplastic Combined Chemotherapy Protocols
Humans
MESH: Antibiotics
Antineoplastic
Carcinoma
Small Cell
Antineoplastic Agents
Alkylating
Cyclophosphamide
MESH: Bronchial Neoplasms
MESH: Etoposide
MESH: Treatment Outcome
Aged
Etoposide
MESH: Aged
MESH: Humans
Antibiotics
Antineoplastic
Bronchial Neoplasms
Remission Induction
MESH: Quality of Life
MESH: Cyclophosphamide
MESH: Carcinoma
Small Cell
MESH: Injections
Intravenous
Antineoplastic Agents
Phytogenic
Survival Rate
MESH: Antineoplastic Combined Chemotherapy Protocols
Treatment Outcome
Doxorubicin
Vincristine
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
MESH: Administration
Oral
Injections
Intravenous
Quality of Life
Health Resources
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Neoplasm Recurrence
Local
MESH: Neoplasm Recurrence
Local
Zdroj: Revue des Maladies Respiratoires
Revue des Maladies Respiratoires, 2007, 24 (5), pp.653-8
ISSN: 0761-8425
1776-2588
Popis: International audience; BACKGROUND: There is no standard second-line treatment for small cell lung cancer (SCLC). The prognosis of these patients is poor and special attention should be paid to both quality of life and economic factors. METHODS: The aim of this phase II randomised trial (GFPC0501) is to compare, in patients with progressive SCLC after first-line platinum based chemotherapy, oral multi drug chemotherapy (CCNU, cyclophosphamide, etoposide) and classical intravenous chemotherapy with cyclophosphamide, doxorubicin and vincristine (CAV) in terms of tolerability, efficacy (response rate, median one year survival and overall survival), quality of life and consumption of health care resources. Based on a two-stage Bryant and Day approach, this study will require a total of 138 patients with an interim analysis of the first 38. EXPECTED RESULTS: This trial will provide information on several aspects of second-line chemotherapy for patients with SCLC. Thirty six patients have been enrolled in 16 centres by December 2006 and the results of the interim analysis will be available in June 2007.
Databáze: OpenAIRE
Externí odkaz: